Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo
- Case Western
Novel pentapeptides called Thrombostatin FM compounds consisting mostly of D-isomers and unusual amino acids were prepared based upon the stable angiotensin converting enzyme breakdown product of bradykinin - RPPGF. These peptides are direct thrombin inhibitors prolonging the thrombin clotting time, activated partial thromboplastin time, and prothrombin time at ≥0.78, 1.6, and 1.6 μm, respectively. They competitively inhibit α-thrombin-induced cleavage of a chromogenic substrate at 4.4--8.2 μm. They do not significantly inhibit plasma kallikrein, factor (F) XIIa, FXIa, FIXa, FVIIa-TF, FXa, plasmin or cathepsin G. One form, FM19 [rOicPaF(p-Me)], blocks α-thrombin-induced calcium flux in fibroblasts with an IC50 of 6.9 ± 1.2 μm. FM19 achieved 100% inhibition of threshold α- or γ-thrombin-induced platelet aggregation at 8.4 ± 4.7 μm and 16 ± 4 μm, respectively. The crystal structure of thrombin in complex with FM19 shows that the N-terminal D-Arg retrobinds into the S1 pocket, its second residue Oic interacts with His-57, Tyr-60a and Trp-60d, and its C-terminal p-methyl Phe engages thrombin's aryl binding site composed of Ile-174, Trp-215, and Leu-99. When administered intraperitoneal, intraduodenal, or orally to mice, FM19 prolongs thrombin clotting times and delays carotid artery thrombosis. FM19, a low affinity reversible direct thrombin inhibitor, might be useful as an add-on agent to address an unmet need in platelet inhibition in acute coronary syndromes in diabetics and others who with all current antiplatelet therapy still have reactive platelets.
- Research Organization:
- Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
- Sponsoring Organization:
- USDOE
- OSTI ID:
- 1006579
- Journal Information:
- J. Thromb. Haemost., Vol. 6, Issue (5) ; 05, 2008
- Country of Publication:
- United States
- Language:
- ENGLISH
Similar Records
Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
Inhibition of tissue factor signaling in breast tumour xenografts induces widespread changes in the microRNA expression profile
Related Subjects
AFFINITY
AGGLOMERATION
AMINO ACIDS
ANGIOTENSIN
BRADYKININ
BREAKDOWN
CALCIUM
CATHEPSINS
CLEAVAGE
CRYSTAL STRUCTURE
ENZYME INHIBITORS
ENZYMES
FIBRINOLYSIN
FIBROBLASTS
IN VITRO
IN VIVO
KALLIKREIN
MICE
PEPTIDES
PLASMA
PROTHROMBIN
RESIDUES
SUBSTRATES
THERAPY
THROMBIN
THROMBOPLASTIN
THROMBOSIS